Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.35 |
| ▸ | IGF1R | P08069 | 8/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20772273 | 0.81 | CYP17A1 (0.40) | CHRNB2CHRNA4CYP17A1P2RX7 | |
| SCHEMBL26621158 | 0.76 | SCN9A (0.37) | CHRNB2CHRNA4CYP17A1IGF1R | |
| SCHEMBL31026164 | 0.76 | CYP17A1 (0.36) | CHRNB2CHRNA4CYP17A1IGF1R | |
| SCHEMBL29011987 | 0.76 | CHRNB2 (0.36) | CHRNB2CHRNA4IGF1R | |
| SCHEMBL30945455 | 0.76 | CYP17A1 (0.36) | CHRNB2CHRNA4CYP17A1IGF1R | |
| SCHEMBL17336541 | 0.76 | NPC1 (0.34) | CHRNB2CHRNA4 | |
| SCHEMBL30983136 | 0.75 | CSNK2A1 (0.35) | CHRNB2CHRNA4CYP17A1IGF1R | |
| SCHEMBL23579469 | 0.75 | CSNK2A1 (0.35) | CHRNB2CHRNA4CYP17A1IGF1R | |
| SCHEMBL15776554 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CYP17A1 | |
| SCHEMBL15614997 | 0.75 | CHRNB2 (0.41) | CHRNB2CHRNA4CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2024-05-16 | — | — | US | disclosed |
| CN-117642392-A | Preparation and application of compounds with immunoregulation function | 上海轶诺药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2022253327-A1 | PREPARATION AND USE OF COMPOUND HAVING IMMUNOMODULATORY FUNCTION | 上海轶诺药业有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-115433210-A | Preparation and application of compound with immunoregulation function | 上海轶诺药业有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20210317136-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210317136-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-112020500-A | Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase | 拉文纳制药公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3728228-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | Ravenna Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| WO-2019043635-A1 | D-AMINO ACID OXIDASE ACTIVITY INHIBITING COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158415-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1B, PIP5K1A, PIP5K1C | CHRNB2 3375/4885CHRNA4 2086/4885CYP17A1 4474/4885 |
| US-11667651-B2 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1B, PIP5K1A, PIP5K1C | CHRNB2 3228/4885CHRNA4 2017/4885CYP17A1 4528/4885 |
| US-20210317136-A1 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | PIP5K1B, PIP5K1A, PIP5K1C | CHRNB2 3228/4885CHRNA4 2017/4885CYP17A1 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.